Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Ozempic is well-known for its ability to manage type 2 diabetes and aid weight loss. . But as more research emerges, additional health benefits of the GLP-1 drug are being uncovered. Previous studies ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more than 40 years, but says when so called GLP-1 drugs made from semaglutide ...